Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
暂无分享,去创建一个
C. Jack | R. Petersen | R. Ivnik | B. Boeve | Glenn E. Smith | D. Knopman | D. Dickson | J. Parisi | G. Smith | J. Whitwell | M. Baker | R. Rademakers | K. Josephs | K. Josephs | W. Hu | D. A. Stroh | J. Whitwell | M. Baker | W. Hu | R. Rademakers | William T L Hu | D. Knopman
[1] D. Dickson,et al. Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration , 2007, Neurobiology of Aging.
[2] John L. Robinson,et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases , 2007, Acta Neuropathologica.
[3] J. Morris,et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. , 2007, The American journal of pathology.
[4] D. Dickson,et al. TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease , 2007, Annals of neurology.
[5] H. Akiyama,et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. , 2007, Brain : a journal of neurology.
[6] Clifford R Jack,et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.
[7] R. Petersen,et al. Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations , 2007, Journal of neuropathology and experimental neurology.
[8] C. Jack,et al. Frontotemporal lobar degeneration without lobar atrophy. , 2006, Archives of neurology.
[9] Bruce L. Miller,et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.
[10] Martin Rossor,et al. Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. , 2006, Archives of neurology.
[11] Julie S. Snowden,et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype , 2006, Acta Neuropathologica.
[12] S. Melquist,et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.
[13] Joseph James Duffy,et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP , 2006, Neurology.
[14] S. Graham,et al. An fMRI study of the Trail Making Test , 2005, Neuropsychologia.
[15] Nick C Fox,et al. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. , 2005, Archives of neurology.
[16] Clifford R. Jack,et al. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease , 2005, NeuroImage.
[17] D. Dickson,et al. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. , 2004, Archives of neurology.
[18] M N Rossor,et al. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry , 2004, Neuropathology and applied neurobiology.
[19] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[20] Thomas E. Nichols,et al. Thresholding of Statistical Maps in Functional Neuroimaging Using the False Discovery Rate , 2002, NeuroImage.
[21] G. Jackson,et al. A Neurocognitive Account of Frontal Lobe Involvement in Orthographic Lexical Retrieval: An fMRI Study , 2001, NeuroImage.
[22] Karl J. Friston,et al. Voxel-Based Morphometry—The Methods , 2000, NeuroImage.
[23] R. Kuzniecky,et al. Visual confrontation naming and hippocampal function: A neural network study using quantitative (1)H magnetic resonance spectroscopy. , 2000, Brain : a journal of neurology.
[24] E. Tangalos,et al. Normative data for the Mattis Dementia Rating Scale. , 1998, Journal of clinical and experimental neuropsychology.
[25] T. Perneger. What's wrong with Bonferroni adjustments , 1998, BMJ.
[26] J. Trojanowski,et al. Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.
[27] E. Tangalos,et al. Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .
[28] John Hardy,et al. Single-day apolipoprotein E genotyping , 1994, Journal of Neuroscience Methods.
[29] James F. Malec,et al. Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .
[30] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[31] Robert A. Bornstein,et al. The Wechsler Memory Scale—Revised , 1990 .
[32] E. Kaplan,et al. The Boston naming test , 2001 .
[33] O'Brien Pc,et al. The appropriateness of analysis of variance and multiple-comparison procedures. , 1983 .
[34] P. O'Brien,et al. The appropriateness of analysis of variance and multiple-comparison procedures. , 1983, Biometrics.
[35] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[36] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[37] P. Rubé,et al. L’examen Clinique en Psychologie , 1959 .
[38] R. Reitan. Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .